kallyope inc  company profile  biocentury publications archives bciq conferences version  free trial  subscribe sign in english   한국어 biocentury menu home  publications  publications home  biocentury bc innovations bc extra bc week in review current issues archives  archives home  basic search advanced search back issues bciq  bciq home  overview pipeline analyst financial analyst company analyst deal analyst conferences  conferences home  newsmakers bio€quity europe future leaders china healthcare summit other industry events elearning  elearning home  videos white papers follow us bciq  company profile bciq overview      settings      support biocentury print this       kallyope inc print preview export bookmark share with colleague general information  location new york ny  region new york state  country us  business category gastrointestinal neurology  year founded 0  website httpwwwkallyopecom  lead product status discovery  archive items are loading  financial information  financing summary  financing details  earnings summary  stocks annual chart  pipeline information  pipeline summary  pipeline details  deals information  deals summary  deals details about biocentury company overview management editorial  research contact contact us advertising  sponsorship career opportunities support forgot password customer service reprints faqs products  solutions products overview publications archives bciq conferences elearning rss feeds legal user agreement terms of use privacy policy your california privacy rights use of images follow us what is biocentury biocentury employs a fully integrated multimedia platform — including publications video online data solutions and conferences — to provide its audience with authoritative and uptodate intelligence about corporate strategy partnering emerging technology clinical data public policy and the financial markets sign in free trial   biocentury inc all rights reserved    terms  conditions  privacy policy set email alert dummy nancy thornberry  kallyope nancy thornberry ceonancy was formerly senior vice president and franchise head diabetes and endocrinology merck  co inc in this role she led discovery and clinical research in diabetes osteoporosis fertility and contraception prior to her role as franchise head nancy initiated and was a leader of merck’s dipeptidyl peptidase  dpp project which resulted in the discovery of januvia® for the treatment of type  diabetes among other notable scientific accomplishments is the identification of the first caspase interleukinβ converting enzyme icecaspase for her scientific contributions she has received numerous awards including the merck presidential fellowship merck directors award heroes of chemistry award by the american chemical society and in 0 received the pharmaceuticals research and manufacturers of america phrma discoverers award which honors research scientists whose work has been of special benefit to humankind in addition to her role at kallyope she serves as a director at intarcia therapeutics and abide therapeuticssee all team news  kallyope news kallyope inc appoints ann e weber and william j rieflin to key rolesoctober 7th 06kallyope inc launches with m series a financing to harness the potential of the gutbrain axisdecember 0th 0 about  kallyope about at kallyope we believe that the gut is the gateway to our internal world containing millions of neurons the gut informs our brains about our wellbeing metabolism and nutritional state the gutbrain axis—the communication highway between our gut and our brain—offers an unprecedented opportunity to access and influence brain centers involved in fundamental human processes an understanding of the biology mediated by the gut and gutbrain circuits will change the way we think about food nutrition and human physiology founded and headquartered in new york city we are developing an industryleading platform to harness the gutbrain axis our crossdisciplinary biotechnology team will integrate cuttingedge technologies in sequencing bioinformatics neural imaging cellular and molecular biology and human genetics to provide an understanding of gutbrain biology that will lead to transformational therapeutics and consumer products to improve human health and nutrition our investors about  kallyope about at kallyope we believe that the gut is the gateway to our internal world containing millions of neurons the gut informs our brains about our wellbeing metabolism and nutritional state the gutbrain axis—the communication highway between our gut and our brain—offers an unprecedented opportunity to access and influence brain centers involved in fundamental human processes an understanding of the biology mediated by the gut and gutbrain circuits will change the way we think about food nutrition and human physiology founded and headquartered in new york city we are developing an industryleading platform to harness the gutbrain axis our crossdisciplinary biotechnology team will integrate cuttingedge technologies in sequencing bioinformatics neural imaging cellular and molecular biology and human genetics to provide an understanding of gutbrain biology that will lead to transformational therapeutics and consumer products to improve human health and nutrition our investors home  kallyope harnessing the gutbrain axis translating cuttingedge science to improve human health about kallyope latest news kallyope inc appoints ann e weber and william j rieflin to key roles our team  kallyope our team nancy thornberry ceo read bio ann weber phd svp  drug discovery read bio rob anstey vp  business development robert barretto phd imaging mio akasako imaging elisa caffrey sequencing weisheng chen phd mouse genetics ian peikon phd sequencing jenny dobson sequencing maja engelstoft phd sequencing jamie fried neuroimaging xiangqing li mouse genetics justin mcmanus phd data science sebastian poliak phd neural circuits charlotte ruby neuroimaging ed schwartz phd imaging dan stettler phd neuroimaging ben van de graaf operations founders tom maniatis phd columbia university read bio charles zuker phd columbia university read bio richard axel md columbia university read bio board of directors amy schulman polaris partners josh wolfe lux capital tim kutzkey phd the column group tom maniatis phd founder william rieflin ngm bio nancy thornberry ceo tony evnin phd strategic advisor terry mcguire strategic advisor scientific advisory board michael brown md university of texas read bio joseph goldstein md university of texas read bio richard scheller phd andme read bio hans clevers md phd hubrecht institute read bio jeffrey friedman md phd the rockefeller university read bio david anderson phd california institute of technology read bio gut scientist  kallyope gut scientist job summary we are seeking a biologist with significant experience in gi physiology and anatomy to work as a member of an integrated team developing robust characterization platforms from human and mouse primary samples and organoids the successful candidate will contribute to the improvement and optimization of existing analyses technologies as well as the development of entirely novel platforms candidates for this role will be well versed in existing technologies for assaying gi physiology especially at the singlecell level as well as a widearray of basicadvanced molecular techniques in addition successful candidates must be able to work effectively both in a collaborative setting and independently and possess outstanding written visual and oral communications skills key responsibilities development and implementation of gi physiological assays development and implementation of singlecell assays for hormone release implementation optimization and improvement of gi organoid technology characterization of biomolecules in tissue samples – immunohistochemistry in situ hybridization highthroughput analyses of metabolites qualifications and education requirements you must have phd and related experience in an academic or industry setting prior experience with gi physiology is required experience with gi physiological assays – including transit time assays etc advanced training in molecular biology including immunohistochemistry in situ hybridization etc experience with flowcytometry andor facs additional preferred experience includes experience working with organoids experience working with singlecells exposure to ngs platforms and library preparation experience with luminex assays elisas demonstrated scientific productivity as evidenced by strong publication record and ability to work effectively in a collaborative setting to apply to apply for this position send us your resume and cover letter to careerskallyopecom back to careers kallyope inc launches with m series a financing to harness the potential of the gutbrain axis kallyope inc launches with m series a financing to harness the potential of the gutbrain axis  team includes trio of highly recognized founders and pharma veteran as ceo platform biotech in new york city represents novel focus on gutbrain axis dec 0 0  et from kallyope inc kallyope inc logo     facebook twitter pinterest kallyope inc logo new york dec 0 0 prnewswireusnewswire  kallyope inc kallyope a biotechnology company focused on harnessing the potential of the gutbrain axis today announced that it has launched with series a financing of  million the new company was founded by charles zuker phd tom maniatis phd and richard axel md and is headquartered at the alexandria center® for life science in new york city the gutbrain axis functions as a twoway information highway between the gut and the brain providing an unprecedented opportunity to access and influence brain centers involved in a variety of fundamental human processes kallyope has put together an exciting stateoftheart program to understand how the gut communicates with other organs and our brains about our physiological metabolic and internal state said tom maniatis phd cofounder of kallyope and a professor in the department of biochemistry and molecular biophysics at columbia university college of physicians and surgeons the company is led by ceo nancy thornberry who brings with her more than 0 years of experience in the pharmaceutical industry thornberry spent more than three decades in research at merck ultimately leading the companys diabetes and endocrinology franchise  we are enormously excited to be developing new ways of influencing gutbrain circuits to improve human health kallyopes crossdisciplinary approach and technology platform have the potential to translate gutbrain biology into a range of new therapeutic and nutritional programs such an approach would not have been possible just a few years ago said kallyope ceo nancy thornberry kallyope will leverage cuttingedge technologies including sequencing genetics circuit mapping neural imaging and bioinformatics the company has already drawn top scientific and analytic talent from institutions like columbia google and bloomberg by integrating and applying complementary tools and approaches to the understanding of gutbrain biology the company aims to develop transformational therapeutics and consumer products that improve human health and nutrition kallyopes founding investors include lux capital polaris partners and the column group other notable investors include illumina inc tony evnin phd and alexandria venture investments what kallyope is doing represents a hugely exciting venture into the untapped therapeutic and nutritional potential of the gutbrain axis which no other biotech has unlocked and translated we believe that kallyope is pioneering an area of science that will fundamentally change how drugs and nutritional products are made targeted and administered said josh wolfe kallyope board member and managing partner of lux capital the company is headquartered in new york city and can draw upon the citys deep talent pool and diverse resources with company headquarters and lab space located at the alexandria center® for life science a stateoftheart collaborative life science campus in the heart of manhattan the company sits in close proximity to new york citys worldleading clinical and research institutions kallyopes founders and the scientific advisory board together encompass numerous members of the national academies two lasker award winners and three nobel laureates kallyopes founders are  charles zuker phd member of the national academy of sciences fellow of the american academy of arts and sciences howard hughes medical institute investigator professor at columbia university and an investigator at the universitys mortimer b zuckerman mind brain behavior institute tom maniatis phd member of the national academy of sciences fellow of the american academy of arts and sciences lasker award recipient professor at columbia university and an investigator at the universitys mortimer b zuckerman mind brain behavior institute richard axel md member of the national academy of sciences fellow of the american academy of arts and sciences nobel laureate howard hughes medical institute investigator professor at columbia university and codirector of the universitys zuckerman institute kallyopes scientific advisory board members are michael brown md nobel laureate joseph goldstein md nobel laureate richard scheller phd lasker award kallyopes board members are  josh wolfe lux capital terry mcguire polaris partners tim kutzkey phd the column group nancy thornberry ceo tom maniatis phd about kallyope inc kallyope is a platform biotechnology company dedicated to unlocking the therapeutic and nutritional product potential of the gutbrain axis the company integrates cuttingedge technologies in sequencing bioinformatics neural imaging cellular and molecular biology and human genetics to provide an understanding of gutbrain biology that will lead to transformational therapeutics and products that improve human health and nutrition the companys founders are charles zuker phd lasker award winner tom maniatis phd and nobel laureate richard axel md headquartered at the alexandria center® for life science in new york city the companys founding investors include lux capital polaris partners and the column group for more information visit wwwkallyopecom logo  httpphotosprnewswirecomprnh997logo   source kallyope inc related links httpwwwkallyopecom view table fullscreen view table fullscreen journalists and bloggers the news you need when you need it join pr newswire for journalists to access all of the free services designated to make your job easier in need of subject matter experts for your story submit a free profnet request and find the sources you need learn more oct 7 06  et preview kallyope inc appoints ann e weber and william j rieflin to key roles my news release contains wide tables view fullscreen looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search kallyope inc appoints ann e weber and william j rieflin to key roles kallyope inc appoints ann e weber and william j rieflin to key roles  ann e weber phd named senior vice president drug discovery william j rieflin appointed to board of directors news provided by kallyope inc oct 7 06  et share this article new york oct 7 06 prnewswireusnewswire  kallyope inc kallyope a biotechnology company focused on harnessing the potential of the gutbrain axis today announced that it has appointed ann e weber phd to the position of senior vice president drug discovery and william j rieflin as an independent member of its board of directors the expansion of kallyopes leadership team reflects the rapid advancement of our platform and confidence in our ability to generate valuable assets said nancy thornberry ceo of kallyope the addition of such highcaliber individuals as ann and bill demonstrates our commitment to getting the right team together to realize the full potential of the gutbrain axis ann e weber phd dr weber will be responsible for taking opportunities arising from the companys stateoftheart technology platform and translating them into drug discovery and development programs  during her year tenure at merck  co where she was most recently vice president lead optimization chemistry her work led to over 0 development candidates including the approved diabetes therapies januvia® sitagliptin janumet® sitagliptin and metformin and marizev® omarigliptin   i am excited to lead the translation of kallyopes integrated platform for the interrogation of gutbrain circuits into new therapeutic opportunities dr weber said i also look forward to working closely again with nancy  dr weber and nancy thornberry previously led the program at merck that resulted in the discovery of januvia® sitagliptin for type  diabetes dr weber is the recipient of numerous awards including the robert m scarborough award for excellence in medicinal chemistry and the heroes of chemistry award both given by american chemistry society acs she has also received phrmas discoverers award recognizing scientists whose work has been of special benefit to humankind and mercks directors award the highest honor that the company confers on its employees she is a 0 liberty science center women in stem honoree and in 06 was named to the acss medicinal chemistry hall of fame dr weber obtained a bs in chemistry summa cum laude from the university of notre dame and a phd in synthetic organic chemistry from harvard university  since leaving merck in november 0 dr weber has been an independent consultant to biotech and pharmaceutical companies including kallyope william j rieflin mr rieflin is chief executive officer of ngm bio and has over 0 years of experience in the biotechnology industry prior to ngm he was president of xenoport inc prior to that he was executive vice president administration chief financial officer general counsel and secretary for tularik inc which was acquired by amgen inc in  previously he was vice president human resources general counsel and secretary for amsco international inc and an associate at sidley  austin llp in the corporate and securities department kallyope is pioneering ways to improve human health and nutrition via the gutbrain axis with a sophisticated and unique technology platform mr rieflin said i look forward to working with the team and board to realize the full potential of this platform in addition to kallyope and ngm mr rieflin serves on the board of directors of flx bio inc mr rieflin earned a bs from cornell university his mba from the university of chicago booth school of business and his jd from stanford law school about kallyope inc kallyope is a platform biotechnology company dedicated to unlocking the therapeutic potential of the gutbrain axis the company integrates cuttingedge technologies in sequencing bioinformatics neural imaging cellular and molecular biology and human genetics to provide an understanding of gutbrain biology that can be translated into transformational therapeutics and products that improve human health and nutrition the companys founders are charles zuker phd lasker award winner tom maniatis phd and nobel laureate richard axel md headquartered at the alexandria center® for life science in new york city the companys founding investors include lux capital polaris partners and the column group for more information visit wwwkallyopecom logo  httpphotosprnewswirecomprnh997logo   to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleaseskallyopeincappointsanneweberandwilliamjrieflintokeyroles507html source kallyope inc related links httpwwwkallyopecom dec 0 0  et preview kallyope inc launches with m series a financing to harness the potential of the gutbrain axis my news release contains wide tables view fullscreen you just read kallyope inc appoints ann e weber and william j rieflin to key roles news provided by kallyope inc oct 7 06  et share this article looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search kallyope inc launches with m series a financing to harness the potential of the gutbrain axis  the business journals menu select a city national albany albuquerque atlanta austin baltimore birmingham boston buffalo charlotte chicago cincinnati columbus dallas dayton denver greensborowinstonsalem honolulu houston jacksonville kansas city los angeles louisville memphis miamifort lauderdale milwaukee minneapolisst paul nashville new york orlando philadelphia phoenix pittsburgh portland raleighdurham sacramento san antonio san francisco seattle silicon valley st louis tampa bay washington dc wichita limited time offer subscribe now search × close sign in sign in your account your account welcome your account sign in existing users create your free account dont have an account your account subscriptions newsletters custom notifications my custom site manage site users sign out sign in sign in your account search home industries  topics all industries  topics banking  financial services career  workplace commercial real estate education energy food  lifestyle government  regulations health care manufacturing media  marketing philanthropy  nonprofits professional services residential real estate retailing sports business technology transportation travel  tourism sponsored content cre now we value your business office environments small business marketing know your neighborhood news news latest news business pulse press releases lists  awards lists all lists build your own lists people  companies companies top private companies find businesses for sale search for company news people people on the move contact top executives executive profiles search for people in the news events events business event calendar nominations more… jobs find or post a job store subscriptions reprints  more how to grow your business advance your career thought leadership trends tips and insights from our partners subscribers manage your account about  contact about the business journals advertise help  faqs call center directory apps  syndication newsletters acbj publications bizwomen upstart hemmings sports business journal inside lacrosse bostinno dcinno chicagoinno austininno select a city national albany albuquerque atlanta austin baltimore birmingham boston buffalo charlotte chicago cincinnati columbus dallas dayton denver greensborowinstonsalem honolulu houston jacksonville kansas city los angeles louisville memphis miamifort lauderdale milwaukee minneapolisst paul nashville new york orlando philadelphia phoenix pittsburgh portland raleighdurham sacramento san antonio san francisco seattle silicon valley st louis tampa bay washington dc wichita follow us twitter linkedin facebook google  press releases kallyope inc launches with m series a financing to harness the potential of the gutbrain axis  team includes trio of highly recognized founders and pharma veteran as ceo  platform biotech in new york city represents novel focus on gutbrain axis dec 0 0 am est new york dec 0 0 prnewswireusnewswire  kallyope inc kallyope a biotechnology company focused on harnessing the potential of the gutbrain axis today announced that it has launched with series a financing of  million the new company was founded by charles zuker phd tom maniatis phd and richard axel md and is headquartered at the alexandria center® for life science in new york city the gutbrain axis functions as a twoway information highway between the gut and the brain providing an unprecedented opportunity to access and influence brain centers involved in a variety of fundamental human processes kallyope has put together an exciting stateoftheart program to understand how the gut communicates with other organs and our brains about our physiological metabolic and internal state said tom maniatis phd cofounder of kallyope and a professor in the department of biochemistry and molecular biophysics at columbia university college of physicians and surgeons the company is led by ceo nancy thornberry who brings with her more than 0 years of experience in the pharmaceutical industry thornberry spent more than three decades in research at merck ultimately leading the companys diabetes and endocrinology franchise  we are enormously excited to be developing new ways of influencing gutbrain circuits to improve human health kallyopes crossdisciplinary approach and technology platform have the potential to translate gutbrain biology into a range of new therapeutic and nutritional programs such an approach would not have been possible just a few years ago said kallyope ceo nancy thornberry kallyope will leverage cuttingedge technologies including sequencing genetics circuit mapping neural imaging and bioinformatics the company has already drawn top scientific and analytic talent from institutions like columbia google and bloomberg by integrating and applying complementary tools and approaches to the understanding of gutbrain biology the company aims to develop transformational therapeutics and consumer products that improve human health and nutrition kallyopes founding investors include lux capital polaris partners and the column group other notable investors include illumina inc tony evnin phd and alexandria venture investments what kallyope is doing represents a hugely exciting venture into the untapped therapeutic and nutritional potential of the gutbrain axis which no other biotech has unlocked and translated we believe that kallyope is pioneering an area of science that will fundamentally change how drugs and nutritional products are made targeted and administered said josh wolfe kallyope board member and managing partner of lux capital the company is headquartered in new york city and can draw upon the citys deep talent pool and diverse resources with company headquarters and lab space located at the alexandria center® for life science a stateoftheart collaborative life science campus in the heart of manhattan the company sits in close proximity to new york citys worldleading clinical and research institutions kallyopes founders and the scientific advisory board together encompass numerous members of the national academies two lasker award winners and three nobel laureates kallyopes founders are  charles zuker phd member of the national academy of sciences fellow of the american academy of arts and sciences howard hughes medical institute investigator professor at columbia university and an investigator at the universitys mortimer b zuckerman mind brain behavior institute tom maniatis phd member of the national academy of sciences fellow of the american academy of arts and sciences lasker award recipient professor at columbia university and an investigator at the universitys mortimer b zuckerman mind brain behavior institute richard axel md member of the national academy of sciences fellow of the american academy of arts and sciences nobel laureate howard hughes medical institute investigator professor at columbia university and codirector of the universitys zuckerman institute kallyopes scientific advisory board members are michael brown md nobel laureate joseph goldstein md nobel laureate richard scheller phd lasker award kallyopes board members are  josh wolfe lux capital terry mcguire polaris partners tim kutzkey phd the column group nancy thornberry ceo tom maniatis phd about kallyope inc kallyope is a platform biotechnology company dedicated to unlocking the therapeutic and nutritional product potential of the gutbrain axis the company integrates cuttingedge technologies in sequencing bioinformatics neural imaging cellular and molecular biology and human genetics to provide an understanding of gutbrain biology that will lead to transformational therapeutics and products that improve human health and nutrition the companys founders are charles zuker phd lasker award winner tom maniatis phd and nobel laureate richard axel md headquartered at the alexandria center® for life science in new york city the companys founding investors include lux capital polaris partners and the column group for more information visit wwwkallyopecom logo  httpphotosprnewswirecomprnh997logo   to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleaseskallyopeinclauncheswithmseriesafinancingtoharnessthepotentialofthegutbrainaxis95html source kallyope inc the information on this page is provided by pr newswire all rights reserved reproduction or redistribution of this content without prior written consent from pr newswire is strictly prohibited is not responsible for this content learn more about this service about pr newswire the information on this page is provided by pr newswire the business journals is not responsible for this content learn more